1.1Sulfonamide linker between fragments
A pyridinesulfonyl chloride reacts with a primary amine to form the sulfur–nitrogen bond. The sulfonamide nitrogen retains a hydrogen-bond donor, and the two sulfonyl oxygens provide acceptor sites.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A pyridinesulfonyl chloride reacts with a primary amine to form the sulfur–nitrogen bond. The sulfonamide nitrogen retains a hydrogen-bond donor, and the two sulfonyl oxygens provide acceptor sites.
A carbon–carbon bond attaches CF₃ to the scaffold at R1. The three fluorine atoms withdraw electron density through sigma bonds around the attachment site.
A carbon–fluorine bond occupies the selected R2 position while the other R2 positions retain their original substituents. The bond removes one carbon–hydrogen oxidation site and introduces a local dipole.
Cyclohexylamine supplies the ring in an amide formed with an activated pyridinecarboxylic acid. The chair conformation provides a six-carbon hydrophobic surface and favors an equatorial orientation for the amide-bearing substituent.
An aromatic oxygen forms an ether bond to a secondary carbon of the cyclopentane ring. The ether oxygen provides a hydrogen-bond acceptor, and the ring presents five saturated carbons as a hydrophobic surface.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A bicyclo[1.1.1]pentan-1-yl group occupies the position of Ar and attaches through a bridgehead carbon. The derivative retains the C(O)NH linkage and hydrogen at R1 and all R2 positions. Coupling the nicotinic acid fragment with bicyclo[1.1.1]pentan-1-amine forms an amide whose nitrogen connects the pyridine carbonyl to the saturated cage.
The test compound has the C(O)NH linkage, a quinolin-6-yl group at Ar, and hydrogen at R1 and all R2 positions. Three sets of sealed vials each contain excess solid in 1.0 mL of phosphate buffer adjusted to pH 7.0 at the test temperature. The sets mix at 15, 25, and 37 °C, with samples taken after 24 and 48 hours. Samples pass through a filter at the test temperature, and liquid chromatography measures the dissolved concentration at each time point.
A side-by-side diffusion cell holds a phospholipid-impregnated porous membrane between stirred donor and receiver chambers. The donor contains a dissolved derivative with the C(O)NH linkage, pyridin-3-yl at Ar, and hydrogen at R1 and all R2 positions. The receiver starts with buffer, and liquid chromatography measures the derivative in timed receiver samples. The slope of cumulative transported amount against time, divided by membrane area, gives the flux.
A molecular graph program stores separate templates for the two amide orientations and identifies the attachment atoms for Ar and R1. The program combines quinolin-6-yl, quinazolin-7-yl, and naphthalen-2-yl fragments with fluorine or cyano at R1 while keeping hydrogen at every R2 position. It checks atom valences, removes duplicate structures with canonical structure strings, and exports the structures with their calculated exact masses.
Activation of pyridine-3-carboxylic acid followed by coupling with an arylamine forms pyridin-3-yl–C(O)–NH–aryl. The carbonyl lies next to the pyridine ring, and the amide nitrogen carries the aryl group.
A nitrile attaches to the scaffold through its carbon atom at R1. The resulting scaffold–C≡N unit presents a linear substituent with a terminal nitrogen that acts as a hydrogen-bond acceptor.
A 5-fluoropyridin-3-yl group connects to the linker through pyridine carbon 3. Fluorine occupies carbon 5, and the ring nitrogen provides a hydrogen-bond acceptor.
R3 is hydroxymethyl, a one-carbon alkyl group bearing a hydroxyl substituent. Direct attachment to Ar gives Ar–CH₂OH, with one methylene group between the aromatic ring and the hydroxyl oxygen.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
In formula (1), the symbol “a” represents either 1 or 2, R0 represents an unsubstituted or substituted amino group, R1 to R4 each represent, independently, a hydrogen atom or an alkyl group, E represents an unsubstituted or substituted alkylene chain, D represents a single bond, oxygen atom, unsubstituted or substituted nitrogen atom, sulfur atom, sulfinyl group, sulfonyl group, carbonyl group, carbonylamino group or aminocarbonyl group, and A represents an unsubstituted or sA · US 2009/0275753 A1 · ¶
(wherein, R1 to R4 each represent, independently, a hydrogen atom or a C1 to C6 alkyl group, and n represents an integer of either 1 or 2).A · US 2009/0275753 A1 · ¶
Ar1 is an aryl group, i.e. a carbocyclic aryl group or heteroaryl group, further including prodrugs, pharmaceutically acceptable salts, racemic mixtures and enantiomers thereof. Said carbocyclic aryl or heteroaryl group may be optionally substituted with one or more alkoxy, halogen, trihaloalkyl (e.g., trifluoromethyl), or lower alkyl radicals.B · US 9,567,324 B2 · ¶ 50
The organic group of R5 represents all functional groups including carbon atom(s), and specific examples include the same groups as those listed within the portion of the specific substituent list provided for the group E, such as a cyano group, alkyl groups, formyl group, amino group, alkenyl groups, alkynyl groups, alkoxy groups, alkenyloxy groups, alkynyloxy groups, aryloxy groups, alkylthiocarbonyl groups, alkylcarbonylamino groups, alkoxycarbonylamino groups, alkoxycarboA · US 2009/0275753 A1 · ¶ 29
R3 is hydrogen, lower alkyl, R4 is hydrogen, lower alkyl, (CH2)nCOOR6 or (CH2)nCOR7;B · US 9,567,324 B2 · claim 1
An empty cell means only that no passage was reproduced there.
However, because the compound exhibits a low blood concentration following administration, and does not necessarily have satisfactory migration properties, it does not provide an adequate medicinal effect when used as an orally-administered drug.A · US 2009/0275753 A1 · ¶ 5
Accordingly, an object of the present invention is to provide an antioxidant drug that exhibits favorable organ migration properties, passes particularly readily through the blood-brain barrier or blood-retina barrier, and even when administered orally, produces a high post-administration blood concentration and satisfactory migration properties.A · US 2009/0275753 A1 · ¶ 6
The present invention is also directed to methods of regulating, modulating or inhibiting tyrosine kinases, whether of the receptor or non-receptor class, for the prevention and/or treatment of disorders related to unregulated tyrosine kinase signal transduction, including cell growth, metabolic, and blood vessel proliferative disorders.B · US 9,567,324 B2 · ¶ 3
Aberrant expression or mutations in the PTKs have been shown to lead to either uncontrolled cell proliferation (e.g. malignant tumor growth) or to defects in key developmental processes.B · US 9,567,324 B2 · ¶ 8
patent.fyi, US 2026/0356803 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356803/, SHA-256 18b456baf0e04129392d4cdb17f4a520a7d753cdbfc4ff6bb97312e822365ea0